Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ARTHNASDAQ:BBLGNASDAQ:HSCSNYSEAMERICAN:VTAK On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.00$0.13$0.16▼$1.57$6K4.024,068 shs8,039 shsBBLGBone Biologics$5.91+11.5%$4.63$3.42▼$25.50$3.22M0.75235,994 shs83,376 shsHSCSHeartSciences$3.76+6.8%$3.56$2.36▼$5.77$4.06M2.57122,420 shs95,380 shsVTAKCatheter Precision$0.30-8.0%$0.28$0.16▼$8.40$3.31M-0.854.45 million shs1.40 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%0.00%+33.33%-99.49%-99.87%BBLGBone Biologics0.00%+24.82%+20.12%+15.88%-21.20%HSCSHeartSciences0.00%+5.32%-5.05%+27.03%-28.38%VTAKCatheter Precision0.00%-17.81%+25.05%-23.86%-95.03%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARTHArch TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ABBLGBone Biologics1.0144 of 5 stars0.05.00.00.01.20.01.3HSCSHeartSciences1.8253 of 5 stars3.53.00.00.00.00.01.3VTAKCatheter Precision0.3237 of 5 stars0.02.00.00.01.10.01.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTHArch Therapeutics 0.00N/AN/AN/ABBLGBone Biologics 0.00N/AN/AN/AHSCSHeartSciences 3.00Buy$13.00245.74% UpsideVTAKCatheter Precision 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTHArch Therapeutics$80K0.07N/AN/A($2.43) per share0.00BBLGBone BiologicsN/AN/AN/AN/A$8.39 per shareN/AHSCSHeartSciences$20K203.04N/AN/A$11.16 per share0.34VTAKCatheter Precision$420K7.87N/AN/A$1.33 per share0.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTHArch Therapeutics-$6.98MN/A0.00∞N/A-8,257.70%N/A-730.22%8/18/2025 (Estimated)BBLGBone Biologics-$4.11MN/A0.00N/AN/AN/A-130.21%-119.39%8/8/2025 (Estimated)HSCSHeartSciences-$6.61M-$7.48N/AN/AN/AN/A-178.80%-109.28%8/4/2025 (Estimated)VTAKCatheter Precision-$16.64MN/A0.00N/AN/A-3,744.91%-153.90%-68.25%8/13/2025 (Estimated)Latest ARTH, HSCS, VTAK, and BBLG EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025BBLGBone Biologics-$2.88-$1.92+$0.96-$0.32N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARTHArch TherapeuticsN/AN/AN/AN/AN/ABBLGBone BiologicsN/AN/AN/AN/AN/AHSCSHeartSciencesN/AN/AN/AN/AN/AVTAKCatheter PrecisionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTHArch TherapeuticsN/A0.100.01BBLGBone BiologicsN/A12.6012.60HSCSHeartSciencesN/A1.020.83VTAKCatheter PrecisionN/A0.210.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTHArch Therapeutics6.91%BBLGBone Biologics34.30%HSCSHeartSciences17.24%VTAKCatheter Precision20.34%Insider OwnershipCompanyInsider OwnershipARTHArch Therapeutics4.50%BBLGBone Biologics6.10%HSCSHeartSciences1.80%VTAKCatheter Precision2.95%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTHArch Therapeutics104.74 million4.53 millionNot OptionableBBLGBone Biologics2545,000504,000Not OptionableHSCSHeartSciences101.08 million1.06 millionNot OptionableVTAKCatheter Precision1411.02 million10.69 millionN/AARTH, HSCS, VTAK, and BBLG HeadlinesRecent News About These CompaniesCatheter Precision, Inc. Addresses Increased Trading Activity in Common StockJune 12, 2025 | quiverquant.comCatheter Precision, Inc. Comments on Recent Market ActivityJune 12, 2025 | globenewswire.comCatheter Precision (VTAK) Reports Key Progress for the LockeT ProductJune 12, 2025 | finance.yahoo.comCatheter Precision, Inc. Secures VIVO Purchase Order From Sahlgrenska University HospitalJune 9, 2025 | finance.yahoo.comCatheter Precision, Inc. Secures VIVO Purchase Order From Sahlgrenska University Hospital | ...June 9, 2025 | gurufocus.comCatheter Precision, Inc. Secures First Order for VIVO Product from Sahlgrenska University Hospital in SwedenJune 9, 2025 | quiverquant.comCatheter Precision, Inc. Receives CE Mark Approval for LockeT, Expanding Market Opportunities in EuropeMay 27, 2025 | quiverquant.comCatheter Precision, Inc. Receives CE Mark for LockeTMay 27, 2025 | globenewswire.comCatheter Precision Enters Market Offering AgreementMay 19, 2025 | tipranks.comCatheter Precision, Inc. Announces First Quarter 2025 Update and Financial ResultsMay 15, 2025 | finance.yahoo.comCatheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and ...May 12, 2025 | gurufocus.comCatheter Precision, Inc. Announces $1.5 Million Private Placement Equity Financing and Potential Strategic AllianceMay 12, 2025 | globenewswire.comCatheter Precision Finalizes Strategic Cardiac AcquisitionMay 8, 2025 | tipranks.comCatheter Precision, Inc. Completes Acquisition of Cardionomic Heart Failure AssetsMay 6, 2025 | finance.yahoo.comNew Clinical Data Presented about VIVO at the 46th Annual Heart Rhythm Association ConferenceMay 1, 2025 | finance.yahoo.comCatheter Precision to Attend and Participate in the 46th Heart Rhythm SocietyApril 24, 2025 | finance.yahoo.comCatheter Precision Acquires Late-Stage Heart Failure Therapy AssetsApril 23, 2025 | theglobeandmail.comCatheter Precision to Acquire Assets in Development for Late-Stage Treatment for Acute Decompensated Heart FailureApril 23, 2025 | finance.yahoo.comCatheter Precision, Inc. Announces Receipt of Audit Opinion with Going Concern DoubtApril 17, 2025 | quiverquant.comCatheter Precision Makes NYSE American Section 610(b) Public AnnouncementApril 17, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingApple’s Quiet HomePad Delay Could Be Its Loudest Move YetBy Chris Markoch | June 1, 2025View Apple’s Quiet HomePad Delay Could Be Its Loudest Move YetARTH, HSCS, VTAK, and BBLG Company DescriptionsArch Therapeutics OTCMKTS:ARTH$0.0012 0.00 (0.00%) As of 06/20/2025Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.Bone Biologics NASDAQ:BBLG$5.91 +0.61 (+11.51%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$5.86 -0.05 (-0.93%) As of 06/20/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1. The company's platform technology is used in delivering enhanced outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. It has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.HeartSciences NASDAQ:HSCS$3.76 +0.24 (+6.82%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$3.64 -0.13 (-3.32%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.Catheter Precision NYSEAMERICAN:VTAK$0.30 -0.03 (-8.03%) Closing price 06/20/2025 04:10 PM EasternExtended Trading$0.30 +0.00 (+0.67%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company sells it products through distribution partners, independent sales agents, and direct employees. Catheter Precision, Inc. is based in Fort Mill, South Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
